Evaluating Safety and Effectiveness of Weekly Alirocumab Doses in Adults with High Blood Cholesterol

What this Trial Is About

Researchers are evaluating an experimental drug called alirocumab for adults with hypercholesterolemia, a condition characterized by high blood cholesterol levels. This Phase 2 study aims to assess the safety and effectiveness of alirocumab when given weekly. The trial also explores other important questions, such as potential side effects and how the drug behaves in the blood over time. Participants will be randomly assigned to one of four study groups receiving different doses of alirocumab, ranging from low to high doses, including a control dose. The drug is administered according to the study protocol on a weekly basis. The study monitors participants for up to 20 weeks to observe the effects and drug levels in the body. During the study, participants will have regular blood tests to measure cholesterol levels and the concentration of alirocumab in their serum. Researchers will track changes in LDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, and other markers through 12 weeks, as well as monitor any treatment-emergent side effects during the 20 weeks. The total study duration lasts until February 2027, with close safety and pharmacokinetic follow-up.

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia